Fresenius Medical Care AGFMCQF 72 PE Ratio without NRI is 9.98 as of Jun. 29, 2026, which is 42% below its 10-year median of 17.30. GuruFocus rates FMCQF with a GF Score™ of 72/100 and a GF Value™ of $45.67 (Fairly Valued). The stock has 4 warning signs investors should review. Among 436 Healthcare Providers & Services companies, Fresenius Medical Care AG ranks better than 85.55% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-29), Fresenius Medical Care AG's share price is $45.17.
Fresenius Medical Care AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $4.53. Therefore, Fresenius Medical Care AG's PE Ratio without NRI for today is 9.98.
During the past 13 years, Fresenius Medical Care AG's highest PE Ratio without NRI was 25.85. The lowest was 9.31. And the median was 17.30.
Fresenius Medical Care AG (OTCPK:FMCQF) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Fresenius Medical Care AG PE Ratio without NRI Related Terms
Fresenius Medical Care AG PE Ratio without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG PE Ratio without NRI Chart
FMCQF vs HCA, THC, DVA: PE Ratio without NRI Comparison
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's PE Ratio without NRI falls into.
Fresenius Medical Care AG PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Fresenius Medical Care AG's Share Price of today is $45.17.
Fresenius Medical Care AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Fresenius Medical Care AG (FMCQF) has a PE Ratio without NRI of 9.98 as of Jun. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Fresenius Medical Care AG and its competitors. This is 42% below median its historical median of 17.30. Over the past decade, Fresenius Medical Care AG's PE Ratio without NRI has ranged from 9.31 to 25.85. According to the industry distribution chart, Fresenius Medical Care AG ranks #63 out of 436 companies in the Healthcare Providers & Services industry, placing it in the top 14.4%.
Is Fresenius Medical Care AG's PE Ratio without NRI too high?
Fresenius Medical Care AG's current PE Ratio without NRI of 9.98 is 42% below median its 10-year median of 17.30. Over the past 10 years, this metric has ranged from a low of 9.31 to a high of 25.85. The Healthcare Providers & Services industry median PE Ratio without NRI is 19.44. Fresenius Medical Care AG's value of 9.98 is 48.6% below this industry median. Based on the distribution chart, Fresenius Medical Care AG ranks #63 out of 436 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Fresenius Medical Care AG has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's PE Ratio without NRI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #63 out of 436 companies for PE Ratio without NRI. This places Fresenius Medical Care AG in the top 14% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 19.44. Fresenius Medical Care AG's value of 9.98 is 48.6% below this benchmark. Historically, Fresenius Medical Care AG's own PE Ratio without NRI has ranged from 9.31 to 25.85 over the past decade. While the company's 10-year median is 17.30 vs. the industry median of 19.44, Fresenius Medical Care AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Healthcare Providers & Services company?
The median PE Ratio without NRI among Healthcare Providers & Services companies is 19.44, based on 436 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius Medical Care AG's current PE Ratio without NRI of 9.98 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Fresenius Medical Care AG and its competitors. For the Healthcare Providers & Services industry, the median PE Ratio without NRI is 19.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius Medical Care AG's current PE Ratio without NRI is 9.98, which is 42% below median its own 10-year median of 17.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (FMCQF) is currently considered Fairly Valued. The stock's GF Value™ is $45.67, compared to a current price of $45.17 — trading 1.1% below its estimated fair value. The current PE Ratio without NRI is 9.98, which is 42% below median its 10-year median of 17.30 and 48.6% below the Healthcare Providers & Services industry median of 19.44. Fresenius Medical Care AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Fresenius Medical Care AG (FMCQF), the current PE Ratio without NRI is 9.98 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (FMCQF) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued.
The current stock price of $45.17 is trading 1.1% below its estimated GF Value™ of $45.67.
GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.
Key valuation signals for FMCQF:
PE Ratio without NRI: 9.98 (42% below median its 10-year median of 17.30)
GF Value™: $45.67 vs. price of $45.17 (1.1% below fair value)
Industry Position: 48.6% below the Healthcare Providers & Services median (#63 of 436)
No single metric tells the full story. See the FMCQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
72GF Score
Get the complete analysis for FMCQF
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FMCQF has been successfully added to your 
